B-cell-targeted therapies, including anti-CD20 monoclonal antibody (Rituximab) and anti-B lymphocyte stimulator (BLyS), are at forefront of new SLE therapies [8, 9] (Table 1). The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.